Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
Sodhi M, Rezaeianzadeh R, Kezouh A, et al. JAMA 2023;330:1795-1797.
What it found
In a US health insurance claims database, people using semaglutide or liraglutide for weight loss had a higher risk of pancreatitis, bowel obstruction and gastroparesis (delayed stomach emptying) than people using the weight-loss drug bupropion-naltrexone. Biliary disease was not significantly different.
Limitations
Short research letter based on claims data, so diagnoses are not confirmed and confounding is possible. These events were rare in absolute terms.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.